Tags

Type your tag names separated by a space and hit enter

Assessment of coenzyme Q10 tolerability in Huntington's disease.
Mov Disord. 1996 May; 11(3):321-3.MD

Abstract

We performed a 6-month open-label trial to evaluate the tolerability and efficacy of coenzyme Q10 (CoQ) in 10 patients with Huntington's disease (HD). Subjects were evaluated at baseline, 3 months, and 6 months using the HD Rating Scale (HDRS), the HD Functional Capacity Scale (HDFCS), and standardized neuropsychological measures. Adverse events (AEs) were assessed by telephone interview every month. CoQ doses ranged from 600 to 1,200 mg per day. All subjects completed the study, although four subjects reported mild AEs, including headache, heartburn, fatigue, and increased involuntary movements. There was no significant effect of the treatment on the clinical ratings. The good tolerability of CoQ suggests that it is a good candidate for evaluation in long-term clinical trials designed to slow the progression of HD.

Authors+Show Affiliations

Department of Neurology, University of Rochester School of Medicine and Dentistry, New York, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8723151

Citation

Feigin, A, et al. "Assessment of Coenzyme Q10 Tolerability in Huntington's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 11, no. 3, 1996, pp. 321-3.
Feigin A, Kieburtz K, Como P, et al. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord. 1996;11(3):321-3.
Feigin, A., Kieburtz, K., Como, P., Hickey, C., Claude, K., Abwender, D., Zimmerman, C., Steinberg, K., & Shoulson, I. (1996). Assessment of coenzyme Q10 tolerability in Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 11(3), 321-3.
Feigin A, et al. Assessment of Coenzyme Q10 Tolerability in Huntington's Disease. Mov Disord. 1996;11(3):321-3. PubMed PMID: 8723151.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of coenzyme Q10 tolerability in Huntington's disease. AU - Feigin,A, AU - Kieburtz,K, AU - Como,P, AU - Hickey,C, AU - Claude,K, AU - Abwender,D, AU - Zimmerman,C, AU - Steinberg,K, AU - Shoulson,I, PY - 1996/5/1/pubmed PY - 1996/5/1/medline PY - 1996/5/1/entrez SP - 321 EP - 3 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 11 IS - 3 N2 - We performed a 6-month open-label trial to evaluate the tolerability and efficacy of coenzyme Q10 (CoQ) in 10 patients with Huntington's disease (HD). Subjects were evaluated at baseline, 3 months, and 6 months using the HD Rating Scale (HDRS), the HD Functional Capacity Scale (HDFCS), and standardized neuropsychological measures. Adverse events (AEs) were assessed by telephone interview every month. CoQ doses ranged from 600 to 1,200 mg per day. All subjects completed the study, although four subjects reported mild AEs, including headache, heartburn, fatigue, and increased involuntary movements. There was no significant effect of the treatment on the clinical ratings. The good tolerability of CoQ suggests that it is a good candidate for evaluation in long-term clinical trials designed to slow the progression of HD. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/8723151/Assessment_of_coenzyme_Q10_tolerability_in_Huntington's_disease_ L2 - https://doi.org/10.1002/mds.870110317 DB - PRIME DP - Unbound Medicine ER -